Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d.
CD1d
L363
alpha-galactosylceramide
beta-mannosylceramide
natural killer T cells
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
26
08
2019
accepted:
18
09
2019
entrez:
26
10
2019
pubmed:
28
10
2019
medline:
29
10
2020
Statut:
epublish
Résumé
iNKT cells are CD1d-restricted T cells recognizing lipid antigens. The prototypic iNKT cell-agonist α-galactosylceramide (α-GalCer) alongside compounds with similar structures induces robust proliferation and cytokine production of iNKT cells and protects against cancer
Identifiants
pubmed: 31649670
doi: 10.3389/fimmu.2019.02355
pmc: PMC6794452
doi:
Substances chimiques
Antibodies, Monoclonal, Murine-Derived
0
Antigens, CD1d
0
CD1d antigen, mouse
0
Galactosylceramides
0
alpha-galactosylceramide
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2355Subventions
Organisme : NIAID NIH HHS
ID : R01 AI045889
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI137230
Pays : United States
Informations de copyright
Copyright © 2019 Clark, Yau, Bloom, Wang, Venzon, Suzuki, Pasquet, Compton, Cardell, Porcelli, Painter, Zajonc, Berzofsky and Terabe.
Références
J Immunol. 2004 Sep 15;173(6):3693-706
pubmed: 15356115
J Immunol Methods. 2007 May 31;323(1):11-23
pubmed: 17442335
J Mol Biol. 2008 Apr 4;377(4):1104-16
pubmed: 18295796
J Biol Chem. 2012 Jan 6;287(2):1269-78
pubmed: 22110136
Oncol Res. 1995;7(10-11):529-34
pubmed: 8866665
J Immunol. 2004 Jan 15;172(2):943-53
pubmed: 14707067
J Exp Med. 2005 Dec 19;202(12):1627-33
pubmed: 16365146
Nature. 2007 Jul 5;448(7149):44-9
pubmed: 17581592
Nat Rev Immunol. 2012 Dec;12(12):845-57
pubmed: 23154222
Cell. 1994 Dec 2;79(5):913-22
pubmed: 8001128
Nat Immunol. 2000 Dec;1(6):459-60
pubmed: 11101862
Nat Immunol. 2005 Aug;6(8):819-26
pubmed: 16007090
Eur J Immunol. 2009 Jul;39(7):1726-35
pubmed: 19582739
Annu Rev Immunol. 2007;25:297-336
pubmed: 17150027
Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):E2616-E2623
pubmed: 28289220
Clin Cancer Res. 2013 Aug 15;19(16):4404-11
pubmed: 23804426
Immunity. 2011 Mar 25;34(3):327-39
pubmed: 21376639
Semin Immunol. 2010 Apr;22(2):68-78
pubmed: 19945296
Adv Cancer Res. 2008;101:277-348
pubmed: 19055947
Nat Immunol. 2005 Aug;6(8):810-8
pubmed: 16007091
J Clin Invest. 2004 Nov;114(10):1379-88
pubmed: 15545985
Science. 1995 Jan 27;267(5197):515-8
pubmed: 7824949
J Exp Med. 2005 Dec 5;202(11):1517-26
pubmed: 16314439
Science. 2004 Dec 3;306(5702):1786-9
pubmed: 15539565
Nat Rev Immunol. 2005 May;5(5):387-99
pubmed: 15864273
J Immunol. 2008 Mar 15;180(6):3627-35
pubmed: 18322166
Nat Rev Immunol. 2004 Mar;4(3):231-7
pubmed: 15039760
Biochemistry. 2003 Dec 23;42(50):14729-40
pubmed: 14674747
Eur J Immunol. 2001 Aug;31(8):2487-96
pubmed: 11500833
J Clin Invest. 2011 Feb;121(2):683-94
pubmed: 21245578
J Immunol. 2011 Sep 1;187(5):2079-83
pubmed: 21810611
J Exp Med. 1996 Oct 1;184(4):1259-68
pubmed: 8879197
Immunity. 2014 Oct 16;41(4):543-54
pubmed: 25367571
Nat Immunol. 2011 Jul 31;12(9):827-33
pubmed: 21804559
J Cell Physiol. 2000 Mar;182(3):311-22
pubmed: 10653597
Biol Pharm Bull. 1995 Nov;18(11):1487-91
pubmed: 8593464
Science. 1997 Nov 28;278(5343):1626-9
pubmed: 9374463
Adv Exp Med Biol. 2007;598:20-34
pubmed: 17892202
Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13433-8
pubmed: 25197085
Science. 1997 Jul 18;277(5324):339-45
pubmed: 9219685
Semin Immunol. 2010 Apr;22(2):61-7
pubmed: 19945889